fda to reconsider tirzepatide UPDATE [March 7, 2025]: OFA takes case appeals court as legal battle evolves Eli Lilly joins FDA as

Drugs do come at a cost. Prime Minister Sir Keir Starmer acknowledged that the government needed to think differently to reduce pressure on the health system and Lilly's CEO, David Ricks, said he welcomed the opportunity to partner with the UK Government on tackling and preventing disease and accelerating innovation to advance care delivery models

USP and CDC multi-dose vial policy require that once a vial is first punctured, it must be date-labeled and discarded within 28 days , regardless of the remaining volume

Previous weight loss drugs relied primarily on stimulating your nervous system or blocking fat absorption, approaches with limited effectiveness and concerning side effects

Medicare will only cover GLP-1 receptor agonists for weight loss if there is a risk of heart disease, in addition to meeting the FDA weight requirements for prescription

Its being studied for more (addiction, mental health, Alzheimers) Prices are coming down (Zepbound is 20% less expensive than Wegovy) But, on the other hand: Medicare is legally prevented from covering GLP1s for obesity Only 16 states cover anti-obesity medications under Medicaid 50% or less commercial plans cover GLP1s for obesity, and those that do often have unreasonable hurdles Covered can still mean $500-1000 out of pocket every month